Everest Medicines Ltd
HKEX:1952
Intrinsic Value
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in G... [ Read More ]
The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 25.44 HKD. Compared to the current market price of 24.1 HKD, Everest Medicines Ltd is Undervalued by 5%.
Valuation Backtest
Everest Medicines Ltd
Run backtest to discover the historical profit from buying and selling Everest Medicines Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Everest Medicines Ltd
| Current Assets | 2.7B |
| Cash & Short-Term Investments | 2.5B |
| Receivables | 77.3m |
| Other Current Assets | 34.4m |
| Non-Current Assets | 3.2B |
| Long-Term Investments | 69.9m |
| PP&E | 679.7m |
| Intangibles | 2.5B |
| Other Non-Current Assets | 7.1m |
| Current Liabilities | 167.3m |
| Accounts Payable | 22.1m |
| Accrued Liabilities | 43.8m |
| Other Current Liabilities | 101.4m |
| Non-Current Liabilities | 310.1m |
| Long-Term Debt | 303.9m |
| Other Non-Current Liabilities | 6.1m |
Earnings Waterfall
Everest Medicines Ltd
|
Revenue
|
125.9m
CNY
|
|
Cost of Revenue
|
-34.4m
CNY
|
|
Gross Profit
|
91.5m
CNY
|
|
Operating Expenses
|
-970.9m
CNY
|
|
Operating Income
|
-879.3m
CNY
|
|
Other Expenses
|
34.9m
CNY
|
|
Net Income
|
-844.5m
CNY
|
Free Cash Flow Analysis
Everest Medicines Ltd
Profitability Score
Profitability Due Diligence
Everest Medicines Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Everest Medicines Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Everest Medicines Ltd
According to Wall Street analysts, the average 1-year price target for Everest Medicines Ltd is 25.45 HKD with a low forecast of 23.58 HKD and a high forecast of 28.35 HKD.
Shareholder Return
Price
Everest Medicines Ltd
| Average Annual Return | -34.27% |
| Standard Deviation of Annual Returns | 23.23% |
| Max Drawdown | -94% |
| Market Capitalization | 7.6B HKD |
| Shares Outstanding | 320 771 494 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 25.44 HKD.
Compared to the current market price of 24.1 HKD, Everest Medicines Ltd is Undervalued by 5%.
You don't have any saved screeners yet
